Search

everythinglearnresearchcommunity

for

Search:↓

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

New steroids were effective in blocking male hormone receptors in hamster prostates.

A new compound was effective for imaging prostate cancer in rats.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early balding at 40 increases prostate cancer risk.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Higher DHT in male baldness may protect against prostate cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Higher cholesterol levels increase aggressive prostate cancer risk.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Suppressing certain hormones might help prevent prostate cancer.